PROCEPT BioRobotics Corporation

NasdaqGM:PRCT Rapporto sulle azioni

Cap. di mercato: US$4.8b

PROCEPT BioRobotics Crescita futura

Future criteri di controllo 2/6

Si prevede che PROCEPT BioRobotics aumenterà gli utili e i ricavi rispettivamente del 44.3% e 24.6% all'anno, mentre si prevede che l'EPS crescerà del 45.8% all'anno.

Informazioni chiave

44.3%

Tasso di crescita degli utili

45.8%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili17.1%
Tasso di crescita dei ricavi24.6%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento14 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27
Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Procept Biorobotics announces $52M debt refinancing

Oct 10

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Sep 19

Procept BioRobotics Has Resources To Ramp Up Commercialization

Sep 01

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

May 26

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10
Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:PRCT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026411-45N/AN/A7
12/31/2025312-71N/AN/A8
12/31/2024223-90N/AN/A8
9/30/2024200-100-104-92N/A
6/30/2024177-104-109-92N/A
3/31/2024156-103-126-104N/A
12/31/2023136-106-133-108N/A
9/30/2023116-107-126-108N/A
6/30/2023102-105-122-109N/A
3/31/202385-98-106-98N/A
12/31/202275-87-83-80N/A
9/30/202261-77-74-72N/A
6/30/202250-69-65-65N/A
3/31/202241-64-61-60N/A
12/31/202134-60-58-57N/A
9/30/202128-57-55-54N/A
6/30/202121-55-53-52N/A
3/31/202114-53-52-52N/A
12/31/20208-53-49-48N/A
12/31/20196-42-51-44N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PRCT rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che PRCT rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che PRCT rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PRCT ( 24.6% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PRCT ( 24.6% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PRCT è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita